Crescendo Equity to invest in Medipost using third blind-pool fund PE firm won't use acquisition financing
Translated by Kim So-in 공개 2022-03-21 08:13:26
이 기사는 2022년 03월 21일 08:08 thebell 에 표출된 기사입니다.
Crescendo Equity Partners is actively making investments using its third blind-pool fund. It recently invested in Seojin System and will acquire a controlling stake in South Korea’s first generation biotech firm Medipost.Crescendo and SkyLake Equity Partners will buy a controlling stake in Medipost for 160 billion won ($131 million), according to industry sources on Thursday. The two private equity (PE) firms will purchase 400,000 shares owned by Medipost chief executive Yang Yoon-sun for 20 billion won, with each injecting 70 billion to purchase convertible preferred shares and convertible bonds.
Crescendo and SkyLake will each invest 80 billion won in the company. Medipost aims to use the proceeds to enter the North American market.
Crescendo plans to fund the entire investment through its third blind-pool fund created in December 2021. The PE firm has believed it would be better to make an equity investment instead of using acquisition financing given the nature of Medipost’s business.
Medipost is the nation’s first generation biotech startup founded in 2000 by Yang. The company is leading the global stem cell therapeutics industry with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell (hUCB-MSC) product named Cartistem for patients with knee Osteoarthritis. Cartistem was released in 2012.
Crescendo targets mid-market companies with high growth prospects to grow them to global players.
The third fund’s investing activities are expected to be accelerated by the the latest investment in Medipost. The fund closed at the end of last year with commitments of 1.1 trillion won, the largest in the firm’s history.
The fund’s first investment was Seojin System. Crescendo decided to purchase Seojin System’s convertible bonds worth 110 billion won in mid-December, 2021. (Reporting by Gyoung-tae Kim)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 경남제약 품는 휴마시스, 유통네트워크·진단키트 '시너지'
- [Company Watch]글로벌텍스프리, 프랑스 자회사 '적자 전환'
- [Red & Blue]'주목도 높아지는 폐배터리' 새빗켐, 침묵 깨고 반등
- [HLB '리보세라닙' 미국 진출기]시장 우려 불식 나선 진양곤, 갑자기 마련된 기자회견
- 효성화학 특수가스 사업부, '경영권 지분 매각'으로 선회
- 한양, 만기도래 회사채 '사모채'로 차환한다
- 동인기연, 'GS 출신' 30년 베테랑 전호철 상무 영입 '성장 방점'
- 에스트래픽, 적자 '일시적 현상'... 2분기 수익개선 기대
- [Company Watch]'자회사 회생신청' 투비소프트, 성과 없는 신사업
- '크라우드 펀딩' 와디즈, '테슬라 요건' 상장 추진